Published in BMJ Open on May 03, 2013
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ (2015) 2.54
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation (2015) 1.66
National Trends in Ambulatory Oral Anticoagulant Use. Am J Med (2015) 1.41
Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc (2013) 1.15
Anticoagulation in atrial fibrillation. BMJ (2014) 0.93
Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circ Cardiovasc Qual Outcomes (2015) 0.83
Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. Thromb J (2014) 0.80
Engaging with quality improvement in anticoagulation management. J Thromb Thrombolysis (2015) 0.78
Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution. Heart Vessels (2015) 0.77
Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study. Medicine (Baltimore) (2016) 0.77
A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution? Vasc Health Risk Manag (2014) 0.77
Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. Biomed Res Int (2014) 0.76
Enhanced elimination of dabigatran through extracorporeal methods. J Med Toxicol (2015) 0.76
Risk of Gastrointestinal Bleeding Among Dabigatran Users - A Self Controlled Case Series Analysis. Sci Rep (2017) 0.75
Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). J Arrhythm (2016) 0.75
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
Review And Insights Into The Bleeding Mechanism Incited By Antithrombotic Therapy: Mechanistic Nuances Of Dual Pro-Hemorrhagic Substrate Incorporating Drug-Induced Microvascular Leakage. J Atr Fibrillation (2015) 0.75
Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation. PLoS One (2016) 0.75
Natural history of bleeding and characteristics of early bleeders among warfarin initiators - a cohort study in Finland. Clin Epidemiol (2016) 0.75
Mechanisms And Management Of Thrombo-Embolism In Atrial Fibrillation. J Atr Fibrillation (2014) 0.75
Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. Eur J Clin Pharmacol (2017) 0.75
Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol (2014) 0.75
Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis (2017) 0.75
Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc (2017) 0.75
Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 5.89
The Danish prescription registries. Dan Med Bull (1997) 5.04
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg (2012) 3.84
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos (2007) 2.47
National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27
[Data validity and coverage in the Danish National Health Registry. A literature review]. Ugeskr Laeger (2001) 2.23
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68
Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol (1997) 1.22
The Danish Registry on Regular Dialysis and Transplantation: completeness and validity of incident patient registration. Nephrol Dial Transplant (2009) 1.19
Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila) (2012) 1.06
Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail (2010) 0.99
Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002. Neuroepidemiology (2006) 0.91
Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost (2012) 0.90
Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med (2013) 20.70
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation (2006) 7.01
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ (2012) 5.63
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21
Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation (2011) 4.90
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet (2009) 3.83
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J (2011) 3.72
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med (2005) 3.35
Is atrial fibrillation an inflammatory disorder? Eur Heart J (2005) 3.33
Prognosis among healthy individuals discharged with a primary diagnosis of syncope. J Am Coll Cardiol (2012) 3.33
Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation (2012) 3.30
Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation (2008) 3.23
Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J (2004) 3.14
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06
The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis (2011) 2.95
Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med (2010) 2.90
Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89
Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA (2015) 2.87
Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA (2012) 2.85
The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol (2008) 2.79
Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens (2009) 2.71
The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ (2012) 2.65
Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64
Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity". J Am Coll Cardiol (2013) 2.61
Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation (2007) 2.59
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation (2006) 2.58
The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J (2003) 2.57